Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

BACKGROUND: We report clinical safety and biochemical efficacy from a dose-ranging study of intravenously administered AVI-4658 phosphorodiamidate morpholino oligomer (PMO) in patients with Duchenne muscular dystrophy. METHOD: We undertook an open-label, phase 2, dose-escalation study (0·5, 1·0, 2·0...

Descripción completa

Detalles Bibliográficos
Autores principales: Cirak, Sebahattin, Arechavala-Gomeza, Virginia, Guglieri, Michela, Feng, Lucy, Torelli, Silvia, Anthony, Karen, Abbs, Stephen, Garralda, Maria Elena, Bourke, John, Wells, Dominic J, Dickson, George, Wood, Matthew JA, Wilton, Steve D, Straub, Volker, Kole, Ryszard, Shrewsbury, Stephen B, Sewry, Caroline, Morgan, Jennifer E, Bushby, Kate, Muntoni, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Publishing Group 2011
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156980/
https://www.ncbi.nlm.nih.gov/pubmed/21784508
http://dx.doi.org/10.1016/S0140-6736(11)60756-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156980/
https://www.ncbi.nlm.nih.gov/pubmed/21784508
http://dx.doi.org/10.1016/S0140-6736(11)60756-3

Ejemplares similares